CHM Share Price Performance
Recent CHM News & Updates
No updates
Chimeric Therapeutics Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0088
- Gross Margin
- 100.00%
- Net Profit Margin
- -873.54%
- Debt/Equity Ratio
- 0%
Chimeric Therapeutics Limited Competitors
About CHM
- Founded
- 2020
- Employees
- n/a
- CEO
- WebsiteView website
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 expressing solid tumors. It also develops CHM CORE-NK that is in phase Ia/IIb clinical trials for acute myeloid leukaemia/colorectal cancer and acute myeloid cancer, as well as in preclinical trials for blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.6%
- 1 Year: 8.6%
- Year to Date: 5.1%
Over the last 7 days, the market has remained flat, although notably the Materials sector declined by 4.2%. Meanwhile, the market is actually up 8.6% over the past year. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading